Drugs / Mitoquinol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05410873 | Jul 2022 → Jun 2024 | dilated cardiomyopathy | Imperial College London | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04026711 Comparator | Jan 2020 → Mar 2024 | asthma, obesity disorder | University of Vermont | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitoquinol | “Mitoquinol mesylate” NCT05410873 ↗ |
| Modality | Small molecule | — CHEMBL4594414 ↗ |